Company Overview
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Why Investors Should Care
Revenue has grown at a 40.4% CAGR over the past five years.
Carries low leverage with a debt-to-equity ratio of 0.13.
Generates positive free cash flow, funding growth and shareholder returns internally.
Recent Developments
- Dec 2025 Revenue of $2.31B (+35.9% YoY); net profit $-208.16M.
- Trailing 12 Months Year-on-year growth — revenue +37.7%.
- 5-Year Trend Long-term compounding — revenue CAGR 40.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | 40.40% |
| 1 Year: | 37.70% |
Stock Price Performance
| 1 Year: | +105.54% |
| 6 Months: | +57.95% |
| 3 Months: | +51.84% |
| 1 Month: | +0.63% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- RSI (14)58.52 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Compounding revenue at 40.4% over 5 years.
- Generates positive free cash flow.
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
No notable concerns flagged.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | NTRA Natera, Inc. R3KPHARMA | 324.14 | -238.34 | $46.72B | 0.00% | -15.84% | -12.54% | 40.40% | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | 49.38M | 52.28M | 55.91M | 52.05M | 62.34M | 63.07M | 65.28M | 66.97M | 66.82M | 74.36M | 77.91M | 83.24M | 94.01M | 86.47M | 98.14M | 152.32M | 142.03M | 158.12M | 194.13M | 198.20M | 210.64M | 241.76M | 261.40M | 268.31M | 367.74M | 413.35M | 439.76M | 501.83M | 546.60M | 592.18M | 665.50M | 696.64M | 752.75M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 185.06M | 200.00M | 207.80M | 220.07M | 245.81M | - |
| Gross Profit | 19.36M | 14.46M | 21.10M | 29.56M | 21.01M | 19.63M | 11.30M | 15.68M | 17.72M | 21.30M | 15.32M | 21.75M | 22.07M | 23.60M | 24.18M | 23.52M | 30.53M | 34.03M | 38.78M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 316.76M | 346.60M | 384.38M | 445.43M | 450.83M | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 395.94M | 456.98M | 481.96M | 468.21M | 544.35M | - |
| Operating Income | -15.47M | -20.74M | - | -9.61M | -22.52M | -26.66M | - | -34.55M | -28.37M | -25.79M | - | -30.52M | -27.22M | -27.17M | - | -31.75M | -28.64M | -21.09M | - | -34.87M | -51.66M | -55.78M | -63.02M | -115.29M | -150.20M | -137.13M | -143.09M | -119.05M | -138.30M | -112.43M | -110.98M | -74.31M | -43.90M | -39.34M | -79.18M | -110.37M | -97.58M | -22.79M | -93.52M | -75.79M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -56.52M | -89.78M | -76.00M | 1.76M | -63.69M | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.00M | 1.03M | 1.04M | 991.00K | 892.00K | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -66.76M | -100.66M | -87.34M | -13.33M | -84.81M | - |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 173.00K | 275.00K | 207.00K | -60.58M | 283.00K | - |
| Net Income | -19.68M | -17.63M | -22.96M | -8.69M | -23.16M | -26.02M | -37.91M | -33.48M | -29.07M | -27.86M | -47.22M | -32.87M | -33.82M | -29.62M | -31.84M | -34.09M | -32.42M | -23.14M | -35.18M | -35.37M | -59.64M | -58.32M | -63.85M | -116.03M | -151.27M | -138.59M | -145.15M | -121.48M | -136.94M | -110.80M | -109.03M | -67.60M | -37.46M | -31.59M | -66.94M | -100.94M | -87.54M | 47.26M | -85.09M | -66.97M |
| Diluted EPS | - | -0.39 | - | -0.17 | -0.46 | -0.50 | -0.72 | -0.65 | -0.55 | -0.52 | -0.90 | -0.61 | -0.62 | -0.49 | -0.51 | -0.54 | -0.48 | -0.33 | -0.46 | - | - | - | -0.74 | -1.32 | -1.63 | -1.45 | -1.50 | -1.25 | -1.23 | -0.97 | -0.95 | -0.56 | -0.30 | -0.26 | -0.50 | -0.74 | -0.64 | - | -0.60 | -0.47 |
| R&D Expense | 6.74M | 7.34M | - | 8.76M | 10.30M | 11.35M | - | 12.65M | 11.79M | 12.61M | - | 14.34M | 11.85M | 12.39M | - | 11.44M | 12.12M | 12.80M | - | 18.23M | 23.00M | 26.42M | 40.19M | 53.75M | 98.46M | 80.41M | 82.58M | 65.51M | 82.31M | 78.17M | 77.23M | 88.64M | 89.11M | 96.93M | 129.08M | 146.43M | 173.41M | - | 210.70M | 228.07M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 55.17M | 159.29M | 190.35M | 212.51M | 209.62M | 257.65M | 302.33M | 391.00M | - | 820.22M | 1.08B | 1.70B | 2.31B |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | 456.26M | 589.83M | 673.75M | 812.93M |
| Gross Profit | - | - | - | - | - | - | - | - | - | 363.97M | 492.74M | 1.02B | 1.49B |
| Operating Expenses | - | - | - | - | - | - | - | - | - | 905.01M | 938.99M | 1.25B | 1.80B |
| Operating Income | -25.27M | 665.00K | -59.84M | -101.05M | -135.34M | -114.63M | -116.29M | -216.28M | - | -541.04M | -446.25M | -222.29M | -309.91M |
| EBITDA | - | - | - | - | - | - | - | - | - | -520.80M | -397.80M | -148.08M | -220.54M |
| Interest Expense | - | - | - | - | - | - | - | - | - | 9.32M | 12.64M | 10.69M | 4.07M |
| Pretax Income | - | - | - | - | - | - | - | - | - | -546.82M | -434.53M | -189.73M | -268.09M |
| Tax Provision | - | - | - | - | - | - | - | - | - | 978.00K | 271.00K | 695.00K | -59.93M |
| Net Income | -37.11M | -5.15M | -70.28M | -100.33M | -137.63M | -128.15M | -124.83M | -229.74M | - | -547.80M | -434.80M | -190.43M | -208.16M |
| Diluted EPS | - | - | -2.68 | -1.95 | -2.59 | -2.22 | -1.79 | -2.84 | - | -5.57 | -3.78 | -1.53 | -1.52 |
| R&D Expense | 11.55M | 17.29M | 27.71M | 41.86M | 50.06M | 51.35M | 51.36M | 100.03M | 264.21M | 316.42M | 320.68M | 404.14M | 624.11M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 123.62M | 265.24M | 210.68M | 214.61M | 268.17M | 582.66M | 932.15M | - | 1.39B | 1.44B | 1.66B | 2.40B |
| Current Assets | - | - | - | - | - | - | - | - | - | - | 1.21B | 1.26B | 1.38B | 1.50B |
| Cash & Equivalents | 5.75M | 30.50M | 87.18M | 28.95M | 15.26M | 12.62M | 46.41M | 61.93M | 48.67M | - | 466.09M | 642.10M | 945.59M | 1.08B |
| Inventory | - | - | - | - | - | - | - | - | - | - | 35.41M | 40.76M | 44.74M | 68.44M |
| Receivables | - | - | - | - | - | - | - | - | - | - | 244.38M | 278.29M | 314.17M | 296.53M |
| Total Liabilities | - | - | 54.35M | 80.47M | 104.20M | 189.20M | 236.01M | 303.94M | 445.92M | - | 688.73M | 676.37M | 465.31M | 685.93M |
| Current Liabilities | - | - | 29.87M | 80.47M | 96.42M | 105.56M | 113.98M | 179.87M | 199.05M | - | 310.50M | 307.27M | 344.05M | 441.23M |
| Long Term Debt | - | - | - | - | - | - | - | - | - | 280.39M | 281.65M | 282.94M | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | 446.22M | 441.99M | 187.12M | 214.38M |
| Total Equity | -136.31M | -171.51M | -171.34M | 226.43M | 143.58M | 25.42M | 32.16M | 278.71M | 486.24M | - | 705.74M | 765.33M | 1.20B | 1.71B |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | 111.25M | 119.58M | 132.65M | 139.69M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | -37.83M | -74.05M | -97.83M | -70.58M | -63.44M | -182.51M | - | -431.50M | -246.96M | 135.66M | 215.30M |
| Investing Cash Flow | - | - | -210.68M | 47.03M | 13.78M | -5.16M | -266.35M | -331.46M | - | 330.34M | 168.50M | 137.62M | -132.21M |
| Financing Cash Flow | - | - | 190.28M | 13.18M | 80.37M | 113.72M | 340.77M | 500.85M | - | 482.64M | 254.46M | 30.20M | 47.46M |
| Capital Expenditure | -8.24M | -9.96M | -7.85M | -23.14M | -9.87M | -3.88M | -4.97M | -19.60M | - | -47.70M | -39.20M | -76.92M | -139.19M |
| Free Cash Flow | - | - | -45.68M | -97.19M | -107.69M | -74.46M | -68.41M | -202.12M | - | -479.20M | -286.15M | 58.75M | 76.11M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | 381.48M | 176.00M | 303.49M | 130.55M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | 44.4% | 45.5% | 60.3% | 64.7% |
| Operating Margin % | -45.8% | 0.4% | -31.4% | -47.6% | -64.6% | -44.5% | -38.5% | -55.3% | - | -66.0% | -41.2% | -13.1% | -13.4% |
| Net Margin % | -67.3% | -3.2% | -36.9% | -47.2% | -65.7% | -49.7% | -41.3% | -58.8% | - | -66.8% | -40.2% | -11.2% | -9.0% |
| ROE % | 21.6% | 3.0% | -31.0% | -69.9% | -541.5% | -398.5% | -44.8% | -47.2% | - | -77.6% | -56.8% | -15.9% | -12.2% |
| ROCE % | - | 0.7% | -32.4% | -88.4% | -124.1% | -74.3% | -28.9% | -29.5% | - | -49.9% | -39.3% | -16.9% | -15.8% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | JPMORGAN CHASE & CO | 8.93% | 12.87M | $4.75B |
| 2 | Blackrock Inc. | 7.57% | 10.91M | $4.03B |
| 3 | Price (T.Rowe) Associates Inc | 6.26% | 9.02M | $3.33B |
| 4 | Vanguard Capital Management LLC | 4.32% | 6.23M | $2.30B |
| 5 | Vanguard Portfolio Management LLC | 4.01% | 5.78M | $2.14B |
| 6 | FMR, LLC | 3.78% | 5.45M | $2.01B |
| 7 | Wellington Management Group, LLP | 2.80% | 4.04M | $1.49B |
| 8 | State Street Corporation | 2.54% | 3.66M | $1.35B |
| 9 | Duquesne Family Office Llc | 2.21% | 3.19M | $1.18B |
| 10 | Geode Capital Management, LLC | 1.91% | 2.75M | $1.02B |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NTRA
New Publication Establishes Strong Clinical Validation of Signatera™ for MRD Assessment in Lymphoma
AUSTIN, Texas, September 01, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced the publication of new data in Blood Neoplasia, validating the prognostic and predictive value of Signa…
Billionaire Stanley Druckenmiller Has Roughly 17% of His $5.2 Billion Duquesne Portfolio in Natera Stock. Is It Still a Buy After an 80% Run?
The billionaire has good reasons to like this genetic testing leader.
Natera & Angiex Partner to Evaluate AGX101 Response With Signatera
NTRA teams with Angiex to use Signatera in a Phase 1 AGX101 trial, aiming to track ctDNA and deepen insights into treatment response.
Natera and Susan G. Komen® Announce National Partnership to Accelerate Progress Against Breast Cancer
AUSTIN, Texas, August 28, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing and precision medicine, today announced a national partnership with Susan G. Komen®, the world’s leading breast cancer organization. Toget…
3 Healthcare Stocks with Promising Prospects
Personal health and wellness is one of the many secular tailwinds for healthcare companies. Players catalyzing medical advancements have benefited from elevated demand, and their momentum is only rising as the industry has posted a 24.9% ga…
Natera and Angiex Partner to Assess Response to Investigational Nuclear-Delivered Antibody-Drug Conjugate™ Using Signatera™
AUSTIN, Texas, August 27, 2026--Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA and precision medicine, today announced a new Signatera collaboration with Angiex, Inc., a privately held biotech company developing a portfolio o…
NTRA — Frequently Asked Questions
What is the current share price of Natera, Inc. (NTRA)?
As of 2026-09-19 21:16 PDT, Natera, Inc. (NTRA) trades at $324.14 on NasdaqGS. Its 52-week range is $157.70 to $338.70.
What is the market capitalisation of NTRA?
Natera, Inc. (NTRA) has a market capitalisation of $46.72B on NasdaqGS.
What is the P/E ratio of NTRA?
NTRA trades at a trailing price-to-earnings (P/E) ratio of -238.34. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 29.12.
What is the return on equity (ROE) of NTRA?
NTRA has a return on equity (ROE) of -12.54%. Its return on capital employed (ROCE) is -15.84%.
Is NTRA a good stock to buy?
This page provides a data-driven analysis of Natera, Inc. (NTRA), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.